Compare
Two to four companies, one screen
The same numbers the feed and each dossier publish, lined up so you can weigh candidates against each other. Every figure is a public-filing estimate, identical for every subscriber, and the shaded cell in a row is simply the highest number in it — not a recommendation.
Add one more to line them up.
| Angiex, Inc. OncologyFormed Remove | |
|---|---|
| Momentum0–100 | 82 |
| Runwayestimate, months | ~118mo |
| Stage | Formed |
| Last raiseForm D, self-reported | $22MSep 26, 2025 |
| Lead investigator | GUO, HAITAO |
| What changed | Study registered, no phase assigned: Comparison of 5% Hypertonic Saline Versus 3% Hypertonic Saline in Resolution of Post-operative Corneal Edema.8w ago · Trial registered |
| Full dossier → |
Momentum and runway are estimates derived from public federal filings, published identically to every subscriber. This is informational only and is not investment advice. How the numbers work